Abstract
For patients with moderate to severe psoriasis, there is a large range of variably effective and safe oral, systemic medications. With appropriate monitoring, these therapies may be used as either monotherapy or in combination with other therapies. Newer drugs in the research pipeline hold significant promise.
Keywords:
Acitretin; Apremilast; Cyclosporine; Methotrexate; Mycophenolate mofetil; Psoriasis; Tofacitinib.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Acitretin / therapeutic use
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
-
Antimetabolites / therapeutic use
-
Cyclosporine / therapeutic use
-
Fumarates / therapeutic use
-
Humans
-
Hydroxyurea / therapeutic use
-
Immunosuppressive Agents / therapeutic use*
-
Isoxazoles / therapeutic use
-
Keratolytic Agents / therapeutic use
-
Leflunomide
-
Methotrexate / therapeutic use*
-
Mycophenolic Acid / analogs & derivatives
-
Mycophenolic Acid / therapeutic use
-
Piperidines / therapeutic use
-
Protein Kinase Inhibitors / therapeutic use
-
Psoriasis / drug therapy*
-
Pyrimidines / therapeutic use
-
Pyrroles / therapeutic use
-
Sulfasalazine / therapeutic use
-
Thalidomide / analogs & derivatives
-
Thalidomide / therapeutic use
-
Thioguanine / therapeutic use
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Antimetabolites
-
Fumarates
-
Immunosuppressive Agents
-
Isoxazoles
-
Keratolytic Agents
-
Piperidines
-
Protein Kinase Inhibitors
-
Pyrimidines
-
Pyrroles
-
Sulfasalazine
-
Thalidomide
-
Cyclosporine
-
tofacitinib
-
Thioguanine
-
Leflunomide
-
Mycophenolic Acid
-
Acitretin
-
apremilast
-
Hydroxyurea
-
Methotrexate